Picture of Modus Therapeutics Holding AB logo

MODTX Modus Therapeutics Holding AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-7%
3m-19.24%
6m-43.27%
1yr-59.75%
Volume Change (%)
10d/3m-41.27%
Price vs... (%)
52w High-70%
50d MA+1.95%
200d MA-36.36%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-94.61%
Return on Equity-502.76%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Modus Therapeutics Holding AB EPS forecast chart

Profile Summary

Modus Therapeutics Holding AB is a Sweden-based biotechnology company that through the patented polysaccharide sevuparin develops the treatment for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    March 31st, 2024
    Incorporated
    May 6th, 2011
    Public Since
    July 22nd, 2021
    No. of Employees
    2
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    se flag iconOMX Nordic Exchange Stockholm
    Shares in Issue
    35,938,899

    MODTX Share Price Performance

    Upcoming Events for MODTX

    Similar to MODTX

    Picture of 2cureX AB logo

    2cureX AB

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Abliva AB logo

    Abliva AB

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Acousort AB logo

    Acousort AB

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Active Biotech AB publ logo

    Active Biotech AB publ

    se flag iconOMX Nordic Exchange Stockholm

    Picture of AddLife AB logo

    AddLife AB

    se flag iconOMX Nordic Exchange Stockholm

    FAQ